Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| AOD-9604 | Thymosin Alpha-1 | |
|---|---|---|
| Category | Growth Factors | Growth Factors |
| Standard Dose | Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach. | Research indicates 1.6 mg administered twice weekly via subcutaneous injection. |
| Timing | Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect. | Morning administration preferred. No food timing restrictions. |
| Cycle Duration | 12-20 week cycles. | 8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance. |
| Evidence Level | moderate_human | strong_human |
AOD-9604 is a synthetic 16-amino acid fragment (residues 176-191) of the C-terminal domain of human growth hormone with a tyrosine substitution at the N-terminus. It selectively stimulates lipolysis by upregulating beta-3 adrenergic receptors in adipose tissue while inhibiting lipogenesis. It modulates lipid and glucose metabolism through beta-adrenergic and AMPK-related pathways without influencing IGF-1 activity, growth, or insulin sensitivity — retaining GH's fat-burning properties without its growth-promoting effects.
Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach.
Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect.
12-20 week cycles.
Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus that acts as a pleiotropic immune modulator through Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) on myeloid and plasmacytoid dendritic cells. It activates downstream IRF3, NF-kB, p38MAPK, and MyD88 signaling pathways to promote cytokine production. It modulates TNF-alpha, IFN-gamma, and IL-2 in CD4+ and CD8+ T lymphocytes by upregulating CD40/CD40L and downregulating PD-L1/PD-1 expression, enhancing both innate and adaptive immunity.
Research indicates 1.6 mg administered twice weekly via subcutaneous injection.
Morning administration preferred. No food timing restrictions.
8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →